Dermatol. praxi. 2026;20(1):11-14 | DOI: 10.36290/der.2026.003

Dermatovenerological specifics of care for transgender patients

MUDr. Kevin Machů
DermaMedEst, s. r. o., Praha a AestheScar s. r. o., Praha

Care of transgender patients represents a complex and multidisciplinary field encompassing medical, dermatological, surgical, and psychosocial aspects. This article focuses on specific issues of dermatological care in transgender individuals in the context of hormone therapy and surgical transition. The effects of androgens and estrogens on the skin and skin appendages are described, including the occurrence of acne, alopecia, and changes in hair growth. Attention is paid to therapeutic options and challenges in the management of these conditions, including isotretinoin therapy and issues related to contraception. Further topics discussed include epilation in relation to gender-affirming surgery, HPV infection in the neovagina, pre-exposure prophylaxis (PrEP), and the risk of skin malignancies. A separate section addresses the importance of aesthetic dermatology and corrective procedures in alleviating gender dysphoria and improving quality of life. In conclusion, the role of the dermatologist as part of the supportive care system for transgender patients and the necessity of an individualized, respectful approach are emphasized.

Keywords: transgender patients, endocrinodermatology, acne, androgenetic alopecia, epilation, PrEP.

Accepted: February 2, 2026; Published: April 8, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Machů K. Dermatovenerological specifics of care for transgender patients. Dermatol. praxi. 2026;20(1):11-14. doi: 10.36290/der.2026.003.
Download citation

References

  1. Yeung H, Kahn B, Ly BC, et al. Dermatologic Conditions in Transgender Populations. Endocrinol Metab Clin North Am. 2019 Jun;48(2):429-440. doi: 10.1016/j.ecl.2019.01.005. PMID: 31027550; PMCID: PMC6497076. Go to original source... Go to PubMed...
  2. Cheung AS, Wynne K, Erasmus J, et al. Position statement on the hormonal management of adult transgender and gender diverse individuals. Med J Aust. 2019 Aug;211(3):127-133. doi: 10.5694/mja2.50259. Epub 2019 Jul 4. PMID: 31271465. Go to original source... Go to PubMed...
  3. Gu Y, Tang GT, Cheung AS, Sebaratnam DF. Dermatological considerations for transgender and gender diverse patients: An Australian perspective. Australas J Dermatol. 2024 Feb;65(1):24-36. doi: 10.1111/ajd.14179. Epub 2023 Nov 2. PMID: 37919972. Go to original source... Go to PubMed...
  4. Thoreson N, Park JA, Grasso C, et al. Incidence and Factors Associated With Acne Among Transgender Patients Receiving Masculinizing Hormone Therapy. JAMA Dermatol. 2021 Mar 1;157(3):290-295. doi: 10.1001/jamadermatol.2020.5347. PMID: 33471082; PMCID: PMC7970334. Go to original source... Go to PubMed...
  5. Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab. 2000 Aug;85(8):2913-21. doi: 10.1210/jcem.85.8.6710. PMID: 10946903. Go to original source... Go to PubMed...
  6. Choe J, Shields A, Ferreira A, et al. Isotretinoin for Acne in Transgender and Gender-Diverse Individuals Receiving Masculinizing Hormone Therapy. JAMA Dermatol. 2024 Jul1;160(7):741-745. doi: 10.1001/jamadermatol.2024.1420. PMID: 38809569; PMCID: PMC11137662. Go to original source... Go to PubMed...
  7. Light AD, Obedin-Maliver J, Sevelius JM, et al. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol. 2014 Dec;124(6):1120-1127. doi: 10.1097/AOG.0000000000000540. PMID: 25415163. Go to original source... Go to PubMed...
  8. Bolognia JL, Schaffer JV, Duncan KO, et al. Alopecias. In: Dermatology Essentials. Philadelphia: PA; 2014:515-523.
  9. Wierckx K, Van de Peer F, Verhaeghe E, et al. Short- and long-term clinical skin effects of testosterone treatment in trans men. J Sex Med. 2014 Jan;11(1):222-9. doi: 10.1111/jsm.12366. Epub 2013 Oct 31. PMID: 24344810. Go to original source... Go to PubMed...
  10. Moreno-Arrones OM, Becerra A, Vano-Galvan S. Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. Clin Exp Dermatol. 2017 Oct;42(7):743-748. doi: 10.1111/ced.13184. Epub 2017 Jul 10. PMID: 28691187. Go to original source... Go to PubMed...
  11. Tang GT, Zwickl S, Sinclair R, et al. Effect of gender-affirming hormone therapy on hair growth: a systematic review of the literature. Clin Exp Dermatol. 2023 Sep 19;48(10):1117-1127. doi: 10.1093/ced/llad203. PMID: 37311161. Go to original source... Go to PubMed...
  12. Ginsberg BA, Calderon M, Seminara NM, et al. A potential role for the dermatologist in the physical transformation of transgender people: A survey of attitudes and practices within the transgender community. J Am Acad Dermatol. 2016 Feb;74(2):303-8. doi: 10.1016/j.jaad.2015.10.013. Epub 2015 Dec 5. PMID: 26669479. Go to original source... Go to PubMed...
  13. Zhang WR, Garrett GL, Arron ST, et al. Laser hair removal for genital gender affirming surgery. Transl Androl Urol. 2016 Jun;5(3):381-7. doi: 10.21037/tau.2016.03.27. PMID: 27298787; PMCID: PMC4893513. Go to original source... Go to PubMed...
  14. van der Sluis WB, Buncamper ME, Bouman MB, et al. Symptomatic HPV-related neovaginal lesions in transgender women: case series and review of literature. Sex Transm Infect. 2016 Nov;92(7):499-501. doi: 10.1136/sextrans-2015-052456. Epub 2016 Mar 24. PMID: 27013740. Go to original source... Go to PubMed...
  15. Mohr S, Gygax LN, Imboden S, et al. Screening for HPV and dysplasia in transgender patients: Do we need it? Eur J Obstet Gynecol Reprod Biol. 2021 May;260:177-182. doi: 10.1016/j.ejogrb.2021.03.030. Epub 2021 Mar 31. PMID: 33836363. Go to original source... Go to PubMed...
  16. Shieh E, Marzinke MA, Fuchs EJ, et al. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. J Int AIDS Soc. 2019 Nov;22(11):e25405. doi: 10.1002/jia2.25405. PMID: 31692269; PMCID: PMC6832671. Go to original source... Go to PubMed...
  17. Mehrotra ML, Westreich D, McMahan VM, et al. Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial. J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):e94-e98. doi: 10.1097/QAI.0000000000002037. PMID: 31192894; PMCID: PMC6578589. Go to original source... Go to PubMed...
  18. Rahmat A, De Nie I, Wiepjes CM, et al. Skin cancer incidence in transgender individuals receiving gender-affirming hormone treatment: a nationwide cohort study in the Netherlands. Int J Dermatol. 2023 Jul;62(7):882-887. doi: 10.1111/ijd.16707. Epub 2023 May 4. PMID: 37140088. Go to original source... Go to PubMed...
  19. Almazan AN, Keuroghlian AS. Association Between Gender-Affirming Surgeries and Mental Health Outcomes. JAMA Surg. 2021 Jul 1;156(7):611-618. doi: 10.1001/jamasurg.2021.0952. PMID: 33909023; PMCID: PMC8082431. Go to original source... Go to PubMed...
  20. de Baun H, Truong T, Beloborodova A, et al. Evaluating the psychosocial impact of gender-affirming dermatology treatments: A systematic review. JEADV Clinical Practice. 2024; 2024;3:385-400. doi: 10.1002/jvc2.357. Go to original source...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.